- Home
- MIRA vs RLYB Comparison
MIRA vs RLYB Comparison
Compare MIRA & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- RLYB
- Stock Information
- Founded
- MIRA 2020
- RLYB 2018
- Country
- MIRA United States
- RLYB United States
- Employees
- MIRA N/A
- RLYB N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- RLYB Health Care
- Exchange
- MIRA Nasdaq
- RLYB Nasdaq
- Market Cap
- MIRA 26.5M
- RLYB 24.1M
- IPO Year
- MIRA 2023
- RLYB 2021
- Fundamental
- Price
- MIRA $1.29
- RLYB $0.57
- Analyst Decision
- MIRA Strong Buy
- RLYB Hold
- Analyst Count
- MIRA 1
- RLYB 2
- Target Price
- MIRA $17.00
- RLYB N/A
- AVG Volume (30 Days)
- MIRA 804.3K
- RLYB 316.7K
- Earning Date
- MIRA 11-11-2025
- RLYB 11-06-2025
- Dividend Yield
- MIRA N/A
- RLYB N/A
- EPS Growth
- MIRA N/A
- RLYB N/A
- EPS
- MIRA N/A
- RLYB N/A
- Revenue
- MIRA N/A
- RLYB $761,000.00
- Revenue This Year
- MIRA N/A
- RLYB N/A
- Revenue Next Year
- MIRA N/A
- RLYB N/A
- P/E Ratio
- MIRA N/A
- RLYB N/A
- Revenue Growth
- MIRA N/A
- RLYB 154.51
- 52 Week Low
- MIRA $0.73
- RLYB $0.22
- 52 Week High
- MIRA $2.56
- RLYB $1.24
- Technical
- Relative Strength Index (RSI)
- MIRA 40.50
- RLYB 49.86
- Support Level
- MIRA $1.19
- RLYB $0.58
- Resistance Level
- MIRA $1.72
- RLYB $0.62
- Average True Range (ATR)
- MIRA 0.10
- RLYB 0.04
- MACD
- MIRA -0.01
- RLYB -0.01
- Stochastic Oscillator
- MIRA 18.25
- RLYB 56.07
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.